本文来源:时代财经 作者:李傲华11月22日,华领医药-B(02552.HK)发布公告称,其全资附属公司华领医药技术(上海)有限公司向拜耳医药保健有限公司(下称“拜耳”)发出书面通知,表示有意自2025年1月1日起,将用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁(多格列艾汀片,dorzagliatin)在中国的商业化责任过渡至华领医药。华领医药与拜耳的此项合作源于2020年8月,双方就华堂宁在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.